Antibody-drug conjugates (ADCs) and immunotherapies are revolutionizing oncology, for example in bladder cancer (enfortumab vedotin + pembrolizumab). However, ADCs only work efficiently if the target structure is present and show “blind spots”. How tumor biology, genetics, surface proteins and tumor microenvironment lead to resistance to ADCs is poorly understood. The scientists therefore use spatial multi-omics and single-cell sequencing to analyze patient tissue from clinical trials (bladder, breast, lung cancer) in order to better understand treatment failure or excellent response. The aim is to identify optimal candidates for existing ADCs based on new diagnostics and to discover target proteins for new ADCs and combine them with immunotherapies to enable more effective and tolerable therapies.